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The science of measuring patient-reported outcomes
(PROs) has advanced substantially in recent decades,
allowing evaluation of how patients feel and function in
clinical research. Assessment of the patient experience
in populations with rare diseases can be successfully
achieved using PRO measures when careful planning
and rigorous methods are employed. A number of
challenges exist when designing and implementing
PRO analyses in rare disease contexts, including het-
erogeneity of outcomes, availability of suitable mea-
sures, recruitment, and selection of appropriate data
collection methods. Strategies to address these exist
and have been employed in past clinical research,
particularly in pediatric populations. PRO assessments
in rare disease clinical trials have been particularly
successful through partnerships between investigators,
PRO methodologists, and patient organizations. The
overall goal of PRO measurement is to understand the
patient experience and it provides an essential part of
evaluating the impact of disease and treatment.
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I n 2011, ruxolotinib was approved by the U.S. Food andDrug Administration (FDA) and European Medicines
Agency (EMA) for use by patients with myelofibrosis, a
rare myeloproliferative neoplasm characterized by cytope-
nias and marked splenomegaly.1 Investigators at the
company developing the drug recognized early that symp-
toms related to the disease were common and often
debilitating. Working with academic collaborators, the
company supported primary qualitative studies in the
patient population to determine which symptoms were most
salient, and then supported creation and testing of a
questionnaire to assess these symptoms.2,3 This process
was conducted with serial consultations with the FDA and
EMA to assure that the methods were satisfactory for a
potential labeling claim of symptomatic benefits.
In the ruxolotinib pivotal phase 3 clinical trial, about 300
patients were randomly assigned to receive study drug or
placebo. Every patient was given a smartphone with which
they reported symptoms daily using a 0–10 numerical rating
scale for each, assessing the worst intensity over the past
24 h.1 Compliance was more than 95%. Results were
striking: 45% of patients receiving the study drug experi-
enced a 50% or greater improvement in symptom score
compared to 5% in the placebo group. The drug was
approved and symptom improvement was included in the
label. The cost of the entire process of developing,
integrating, and analyzing the symptom data accounted for
less than 3% of the overall program budget.
A “patient-reported outcome” or “PRO” has become the
preferred terminology for a data element directly reported
by patients or their surrogates about experiences with care
and preferences, including symptoms, functional status, or
quality of life.4 Multiple entities have produced guidance
documents offering standards for developing, assessing,
implementing, and analyzing PROs, including regulatory
agencies like the FDA,5 publishing standards organizations
like CONSORT,6 quality standards organizations such as
the National Quality Forum (NQF),7,8 and professional
associations like the International Society for Quality of
Life Research (ISOQOL)9 and the International Society for
Pharmacoeconomics and Outcomes Research (ISPOR).10
The growing number of organizations representing the
interests of people with rare diseases understandably
includes a focus on how people feel and function, which
requires measurement with PRO tools. Highly motivated
populations and advocacy organizations can facilitate
collection of patient-reported information. The example of
ruxolitinib is informative, as the high compliance rate
reflects patients’ willingness and enthusiasm to participate
in data generation. Nonetheless, PROs are still omitted from
many trials, and therefore do not appear in the publications
of trial results or drug labels, particularly in evaluations of
rare diseases.11,12
However, many of the challenges presented by assessing
PROs in rare diseases can be addressed with careful
planning and by drawing on established and current PRO
research. The much smaller patient population is a
significant impediment to recruiting enough patients to
clinical trials as well as to studies designed to develop or
validate a PRO for that condition.13 In both cases, patient
advocacy groups and clinical care networks are potential
avenues for patient recruitment. For both rare and more
common diseases, the primary challenge in assessing PROsPublished online July 17, 2014
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in a clinical trial is identifying a questionnaire that has
appropriate content and a feasible method of data collection
for the patients and their disease. In June 2011, the
EveryLife Foundation workshop on Clinical Evaluation of
Rare Disease Treatments featured a practical, in-depth
review of methods for selecting and adapting PROs for
rare disease clinical trials.14
Nevertheless, it is not possible to collect PROs from all
study participants. Observer-Reported Outcomes (ObsROs)
may be used to assess observable symptoms and function-
ing when patients are too young, too ill, or have cognitive
impairments that make them unable to respond to PRO
survey questions. When patients are able to report their
experience but have physical impairments to completing
paper, computer, or automated phone surveys, PROs may
be collected via an interviewer. ISPOR has published a
guidance document for development and use of ObsROs
and PRO assessment in pediatrics.15 Because many people
with rare diseases are children, this is informing their
development of recommendations for PRO assessment in
rare disease clinical trials.16
If there is substantial heterogeneity in how the disease
presents, there may not be discrete outcomes that are
measureable across the population. A multi-attribute ques-
tionnaire may be used in such cases, as it was (successfully)
in the case of ruxolitinib. Investigators with experience in
PRO measure development and use must be engaged early
in a research program. This may involve an academic
collaboration, or hiring a PRO consulting firm, as the
developers of ruxolitinib did.
Off-the-shelf questionnaires may not be appropriate or
specific enough to measure the important outcomes in a
particular rare disease, and considerable effort may be needed
to develop and test PRO tools. Additionally, if a drug is being
developed towards regulatory approval, discussion with the
applicable agencies is necessary to assure the PRO measure-
ment strategy is compatible with their standards. There has
been a recent resurgence in the development of instruments
that are concept specific (i.e., pain, fatigue, physical function)
instead of disease specific, such as the National Institutes of
Health (NIH) Patient Reported Outcomes Measurement
Information System (PROMIS) measures,17 which is a boon
for rare disease research because disease-specific measures are
often not available.
Although challenges exist for assessing PROs when a
condition is rare, many of the barriers are inherent to
studying rare diseases rather than PRO measurement itself.
The current body of research in PRO assessment methods
and newly developed tools provide substantial knowledge
and resources for rare disease clinical investigators. PRO
assessments have been particularly successful through
partnerships among clinical investigators, PRO methodolo-
gists, and patient organizations. Understanding how patients
feel is essential information when characterizing a disease
or a treatment. Arguably, without such information, our
understanding of either one remains incomplete.
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